nedaplatin

01/01/2011 - "However, due to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with cervical cancer. "
01/01/2010 - "Nedaplatin-based concurrent chemoradiotherapy was safely performed and significantly improved the prognosis of patients with FIGO stage IIIb cervical cancer. "
12/01/2009 - "Postoperative nedaplatin-based CCRT was safely performed and improved the prognosis of FIGO stage IA2-IIB cervical cancer patients displaying high-risk or intermediate-risk prognostic factors. "
01/01/2011 - "Based on the promising results of preclinical studies, the clinical efficacy of nedaplatin as a radiosensitizing agent was evaluated in patients with cervical cancer. "
06/01/1992 - "Based on these results, it was concluded that 254-S is a very useful anticancer agent for the treatment of cervical cancer."

02/01/2000 - "The observations suggested that 254-S, which has little or no side effects including nephrotoxicity, can become the standard remedy for esophageal cancer instead of CDDP in future."
10/01/2002 - "[Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer]."
09/01/2004 - "This is a report of a case with esophageal cancer in which pathological CR was obtained by neoadjvant chemoradiotherapy using a low-dose of nedaplatin (CDGP)/5-FU. "
02/01/1999 - "A 60-year-old male with type 2 advanced esophageal cancer, which was located in the upper part of the esophagus and had invaded adjacent organs, was treated with nedaplatin 150 mg/body (100 mg/m2) given intravenously every 4 weeks from January 6, 1991. "
04/01/1992 - "Based on these results, it was concluded that 254-S is a useful anticancer agent for the treatment of esophageal cancer."

03/01/2006 - "Nedaplatin is effective in the treatment for HNSCC, NSCLC and ovary carcinoma. "
01/01/2007 - "In order to evaluate the safety and efficacy of chemoradiotherapy using nedaplatin for locally advanced uterine cervical carcinoma in Japanese patients, we have started a single-institute phase II trial. "
12/01/2006 - "This study was to evaluate the efficacy of home-produced Nedaplatin in China on esophageal carcinoma, and observe its toxicity. "
01/01/2008 - "Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis."
01/01/2007 - "Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)."

12/01/2013 - "We performed a pharmacokinetic phase I trial of the combination of S-1 granules and nedaplatin for head and neck squamous cell carcinoma (HNSCC). "
01/01/2013 - "Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma."
06/01/2008 - "The purpose of this study was to evaluate the effectiveness and safety of concurrent chemoradiotherapy using weekly nedaplatin for the treatment of locally advanced squamous cell carcinoma of the uterine cervix. "
05/01/2007 - "The present study evaluated the efficacy and safety of nedaplatin-combination therapy (NDP/5-FU [5-FU arm] or NDP/S-1 [S-1 arm] ) for the treatment of oral squamous cell carcinoma. "
01/01/2007 - "Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix."

12/01/2009 - "A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer."
12/01/2002 - "The aim of this study was to observe the efficacy and the side effects of nedaplatin in treatment of non-small cell lung cancer (NSCLC). "
04/01/2007 - "Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma."
12/01/2002 - "[Phase II clinical trial of nedaplatin in advanced non-small cell lung cancer]."
01/01/1990 - "We conclude that as a single agent, 254-S is well tolerated but appears to have marginal activity against non-small-cell lung cancer."